Temasek Holdings Private Ltd Purchases 678,917 Shares of Boston Scientific Corporation $BSX

Key Points

• Temasek Holdings Private Ltd has increased its stake in Boston Scientific Corporation by 167.0% during the 1st quarter, now owning over 1 million shares valued at approximately $109 million.
• Boston Scientific reported a 22.8% year-over-year increase in quarterly revenue, reaching $5.06 billion and exceeding analysts' expectations.
• Several hedge funds increased their stakes in Boston Scientific, with institutional investors now owning 89.07% of the company's stock, indicating strong market confidence.

Temasek Holdings Private Ltd grew its position in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 167.0% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,085,411 shares of the medical equipment provider's stock after buying an additional 678,917 shares during the period. Temasek Holdings Private Ltd owned about 0.07% of Boston Scientific worth $109,496,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in BSX. NS Partners Ltd raised its position in shares of Boston Scientific by 1.6% during the 1st quarter. NS Partners Ltd now owns 368,189 shares of the medical equipment provider's stock worth $37,143,000 after purchasing an additional 5,704 shares during the period. Bank Pictet & Cie Europe AG boosted its holdings in shares of Boston Scientific by 40.8% in the fourth quarter. Bank Pictet & Cie Europe AG now owns 73,096 shares of the medical equipment provider's stock valued at $6,529,000 after acquiring an additional 21,173 shares in the last quarter. Oppenheimer & Co. Inc. boosted its holdings in Boston Scientific by 18.8% during the first quarter. Oppenheimer & Co. Inc. now owns 39,523 shares of the medical equipment provider's stock worth $3,987,000 after buying an additional 6,264 shares in the last quarter. Segall Bryant & Hamill LLC bought a new stake in Boston Scientific during the first quarter worth approximately $8,234,000. Finally, Blue Trust Inc. lifted its position in shares of Boston Scientific by 13.0% in the 1st quarter. Blue Trust Inc. now owns 5,000 shares of the medical equipment provider's stock valued at $504,000 after acquiring an additional 575 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, EVP Arthur C. Butcher sold 17,313 shares of the business's stock in a transaction on Friday, August 1st. The shares were sold at an average price of $104.63, for a total value of $1,811,459.19. Following the sale, the executive vice president owned 23,600 shares of the company's stock, valued at $2,469,268. The trade was a 42.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the company's stock in a transaction on Friday, August 1st. The stock was sold at an average price of $104.63, for a total transaction of $5,231,500.00. Following the sale, the executive vice president directly owned 178,342 shares in the company, valued at $18,659,923.46. This trade represents a 21.90% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 174,214 shares of company stock worth $18,397,457. Company insiders own 0.50% of the company's stock.

Wall Street Analyst Weigh In

BSX has been the subject of a number of research analyst reports. UBS Group increased their target price on shares of Boston Scientific from $130.00 to $135.00 and gave the stock a "buy" rating in a research report on Thursday, July 24th. Oppenheimer upgraded shares of Boston Scientific from a "market perform" rating to an "outperform" rating and increased their target price for the stock from $118.00 to $125.00 in a research report on Monday. Wells Fargo & Company raised their price target on shares of Boston Scientific from $118.00 to $124.00 and gave the company an "overweight" rating in a report on Thursday, July 24th. Needham & Company LLC reissued a "buy" rating and set a $115.00 target price on shares of Boston Scientific in a research report on Wednesday, May 28th. Finally, Truist Financial upped their price target on Boston Scientific from $120.00 to $125.00 and gave the stock a "buy" rating in a research note on Thursday, July 24th. Three research analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and one has given a Hold rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $117.79.

Boston Scientific Stock Performance

NYSE BSX traded down $2.77 during midday trading on Wednesday, hitting $105.32. The company had a trading volume of 10,384,952 shares, compared to its average volume of 7,468,574. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49. The stock has a market cap of $156.06 billion, a price-to-earnings ratio of 62.69, a P/E/G ratio of 2.60 and a beta of 0.65. The firm has a fifty day simple moving average of $104.85 and a two-hundred day simple moving average of $102.22. Boston Scientific Corporation has a fifty-two week low of $80.64 and a fifty-two week high of $109.50.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.72 by $0.03. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The firm had revenue of $5.06 billion during the quarter, compared to the consensus estimate of $4.89 billion. During the same period last year, the firm posted $0.62 EPS. The firm's quarterly revenue was up 22.8% on a year-over-year basis. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Equities analysts forecast that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.